Floatz logo

Allogeneic Bone Marrow-Derived Mscs

Myeloablative Chemotherapy Induced Bone Marrow Aplasia

Burnasyan Federal Medical Biophysical CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Myeloablative Chemotherapy Induced Bone Marrow Aplasia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2/3BBB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB
Busulphan
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3BB

View all 37 →

Same molecule, other indications

Allogeneic Bone Marrow-Derived Mscs is also rated in:

lumbar disk degenerative disorderDormant
CCC
Indicative ·
54 / 100
View asset →
bipolar depressionDormant
CC
Indicative ·
43 / 100
View asset →
Platinum-Resistant Fallopian Tube CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →